Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Declines By 23.3%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 235,700 shares, a decrease of 23.3% from the September 30th total of 307,400 shares. Based on an average daily trading volume, of 270,800 shares, the short-interest ratio is currently 0.9 days. Currently, 1.6% of the shares of the stock are short sold.

NeuroSense Therapeutics Stock Up 5.0 %

Shares of NASDAQ:NRSN traded up $0.06 during midday trading on Friday, hitting $1.27. The stock had a trading volume of 331,765 shares, compared to its average volume of 264,269. The company’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.08. NeuroSense Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $2.33. The company has a market capitalization of $17.36 million, a P/E ratio of -1.49 and a beta of 1.57.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. XTX Topco Ltd purchased a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned approximately 0.24% of NeuroSense Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.